MDI Announces Renaming Detect-Ready MRSA Screening Test and Distribution Agreement
Westburg will supply the diagnostic in the Benelux region.!--h2>
Molecular Detection (MDI) entered into an exclusive agreement with Westburg for distribution of MDI’s Detect-Ready MRSA panel in the Benelux region. In a separate announcement, MDI renamed its Detect-Ready test in recognition of the fact that it is now CE-marked in the EU for the detection of MRSA, methicillin-sensitive S. aureus (MSSA), methicillin-resistant non-S. aureus, and mixed samples. Its new name is the Detect-Ready MRSA panel.
The Detect-Ready MRSA kit is a qualitative real-time PCR (rt-PCR) in vitro diagnostic test. It aids in the prevention and control of MRSA, MSSA, and methicillin-resistant non-S. aureus infections in hospitals and other healthcare settings. It reportedly provides a unique differential diagnosis that produces accurate results, minimizing false positives and false negatives experienced with other screening kits.
Samples for testing are obtained using nasal swabs, and the kit's ready-to-use premixed reagents require only the addition of patient sample to run the test, which provides results in less than three hours. Unlike other testing products that require special handling, Detect-Ready kits are off-the-shelf, room temperature-stabilized, and require no refrigeration.
Detect-Ready kits are compatible with multiple rt-PCR platforms including the Roche LightCycler®, Qiagen Rotor-Gene®, and Cepheid SmartCycler®. It is currently available in Australia, Austria, Germany, Ireland, Spain, Switzerland, and U.K.